Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for patients with refractory soft tissue sarcoma.

Mikiya Ishihara,Hiroyoshi Hattori,Eisuke Arai,Yoshihiro Nishida,Kohichi Takada,Makoto Emori,Akira Kawai,Takafumi Ueda,Makoto Endo,Yoshihiro Matsumoto,Tetsuro Sasada,Eiichi Sato,Tomomi Yamada,Akihiko Matsumine,Yasuhiro Nagata,Naozumi Harada,Hiroshi Shiku,Shinichi Kageyama

Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for patients with refractory soft tissue sarcoma.

2019

Mikiya Ishihara
Hiroyoshi Hattori
Eisuke Arai
Yoshihiro Nishida
Kohichi Takada
Makoto Emori
Akira Kawai
Takafumi Ueda
Makoto Endo
Yoshihiro Matsumoto
Tetsuro Sasada
Eiichi Sato
Tomomi Yamada
Akihiko Matsumine
Yasuhiro Nagata
Naozumi Harada
Hiroshi Shiku
Shinichi Kageyama

TPS11074Background: Combination therapy to enhance the efficacy of T cell receptor (TCR)-engineered T cells (TCR-T) has received increasing attention. We found that a combination therapy of TCR-T a...

Keywords:

T-cell receptor
Refractory
NY-ESO-1
Combination therapy
Clinical trial
Soft tissue sarcoma
Pathology
Cancer research
Medicine
T cell
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations